SeeQ Diagnostics provides a rapid, on-site metagenomic platform for identifying pathogens directly from human blood samples. Their integrated workflow, combining proprietary DNA enrichment chemistry and rapid sequencing, delivers accurate results within 6-8 hours, enabling timely clinical decisions.
Funding
Funding not disclosed
Founders
Product
Problem
Current methods for identifying pathogens in human blood require extended turnaround times, often delaying critical clinical decisions. This delay can negatively impact patient outcomes, particularly in acute care settings where rapid diagnosis is essential for effective treatment.
Solution
SeeQ Diagnostics offers an integrated metagenomic platform for rapid, on-site pathogen identification directly from human blood samples. The system leverages proprietary chemistry for microbial DNA enrichment, coupled with state-of-the-art rapid sequencing technology. This workflow is supported by specialized bioinformatics software that processes raw sequence data to deliver accurate pathogen identification within a 6-8 hour timeframe. This accelerated diagnostic capability enables clinicians to make timely treatment decisions, thereby improving patient management and outcomes.
Target Audience
The primary target audience includes hospital emergency departments, clinical laboratories, and infectious disease specialists who require rapid and accurate pathogen identification from blood cultures.
Features
- Novel chemistry for enhanced microbial DNA enrichment in human blood samples.
- Integrated workflow combining liquid handling robotics and rapid sequencing for on-site analysis.
- Proprietary bioinformatics software for DNA sequence classification and pathogen identification.
- Delivers results within a 6-8 hour turnaround time.
- Utilizes know-how developed for rapid viral variant tracking, adapted for broad pathogen detection.
- Demonstrated 100% sensitivity compared to gold-standard blood culture with MALDI-TOF identification in a clinical study.
- Capable of identifying pathogens in additional patients missed by standard methods.